[1] WHO1. Cervical cancer. Accessed April 8, 2022.
[2] 李双, et al. "人乳头瘤病毒疫苗临床应用中国专家共识." 中国医学前沿杂志 (电子版) (2021).
[3] Laura Q.M. Chow, M.D. Head and Neck Cancer. N Engl J Med 2020;382:60-72
DOI: 10.1056/NEJMra1715715
[4] 张学军, 郑捷. 皮肤性病学[M]. 第 9 版. 北京: 人民卫生出版社. 2018: 72.
[5] Paz-Zulueta, M., Álvarez-Paredes, L., Rodríguez Díaz, J. C., Parás-Bravo, P., Andrada Becerra, M., Rodríguez Ingelmo, J. M., ... & Santibañez, M. (2018). Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions. BMC cancer, 18(1), 1-9.
[6] 中华预防医学会疫苗与免疫分会. 子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识[J]. 中华预防医学杂志, 2019, 53(8):761-803.
[7] Information About the Human Papillomavirus (HPV). WebMD. Accessed April 8, 2022.
[8] China:Human Papillomavirus and Related Diseases Report.
[9] Serrano B, de Sanjosé S, Tous S, et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015;51(13):1732-1741. doi:10.1016/j.ejca.2015.06.001
[10] Gu, W., Zhang, P., Zhang, G., Zhou, J., Ding, X., Wang, Q., ... & Zhu, Y. (2020). Importance of HPV in Chinese penile cancer: a contemporary multicenter study. Frontiers in oncology, 1521.